

Mary M. Spolyar, MD

Dawes Fretzin Clinical Research Group, LLC
7910 North Shadeland Avenue
Indianapolis, Indiana 46250
Phone (317) 516-5030
Fax (317) 516-5031
E-mail: marydgcrg@gmail.com

Dawes Fretzin Dermatology Group, LLC
7910 North Shadeland Avenue
Indianapolis, Indiana 46250
Phone (317) 516-5000
Fax (317) 516-5031

Education

Naval Medical Center San Diego (San Diego, CA)
Dermatology Residency, 2000-2003

Naval Operational Medical Institute (Pensacola, FL)
Designated United States Naval Flight Surgeon, 1998

Naval Medical Center San Diego (San Diego, CA)
Transitional Internship, 1996-1997

Indiana University School of Medicine (Indianapolis, IN)
Doctor of Medicine, 1996

Yale University (New Haven, CT)
Bachelor of Arts in American Studies, 1989

Professional Experience

Dawes Fretzin Clinical Research Group, LLC (Indianapolis, IN)
Sub-Investigator, July 2009 - Present

Dawes Fretzin Dermatology Group, LLC (Indianapolis, IN)
Dermatologist, July 2009 - Present

West Kentucky Dermatology (Owensboro, KY)
Dermatologist, 2006-2008

U.S. Navy

*Naval Medical Center, Portsmouth, VA; Dermatologist, Lieutenant Commander
2003-2006*

*Naval Medical Center, San Diego, CA; Dermatology Resident
2000-2003*

*Marine Corps Air Station, Beaufort, SC; US Naval Flight Surgeon VMFA(AW) 224
Marine Aircraft Group 31
1998-2000*

*Naval Air Station North Island, Coronado, CA; General Medical Officer
1997*


7/19/24

Mary M. Spolyar, MD

Honors and Awards

Outstanding Transitional Year Intern 1996-97 Naval Medical Center San Diego
National Defense Service Medal (Two awards)
Navy Sea Service Deployment Ribbon
Marine Corps Overseas Service Ribbon
Meritorious Unit Commendation (Two awards)

Articles and Publications

William H. Sturgill LCDR, MC, USNR, Brian C. Leach MAJ, MC, USAF, Mary M. Spolyar, LCDR, MC, USNR, and E. Victor Ross CAP, MC, USN: Evaluation of a Novel Flash Lamp System Incorporating Optimal Spectral Filtration for the Treatment of Photoaging. *Lasers in Surgery and Medicine* 9999:1-6 (2005).
Bruce A. Chabner, Susan E. Bates, Antonio T. Fojo, Mary Spolyar, and Wyndham H. Wilson: Drug Resistance in Adult Lymphomas. *Seminars in Hematology* Vol. 31, No. 1 (January): 70-87, 1994.
Susan E. Bates, Jong Seok Lee, Bruce Dickstein, Mary Spolyar, and Antonio T. Fojo: Differential Modulation of P-Glycoprotein Transport by Protein Kinase Inhibition. *Biochemistry* 1993, Vol. 32: 9156-9164.

Clinical Experience

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 24-week Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) Extended Release Tablets in Subjects with Moderate to Severe Plaque Psoriasis. PPC-06-CD-004

An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated with Calcipotriene Ointment. SNA-120-202

A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients with Plaque Psoriasis: 1957-201-001

A Multicenter, Randomized, Double-Blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis: CNTO1959PSO3009

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to explore changes in subcutaneous adipose tissue and modulation of skin inflammation after 12 weeks of treatment with secukinumab, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult patients with moderate to severe plaque psoriasis (ADIPSO): CAIN457AUS07

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of PF-06700841 in Subjects with Moderate to Severe Plaque Psoriasis. B7931004

A Multicenter, Open-Label Study to assess the safety and efficacy of risankizuMab for maintenance in moderate to severe plaque type psoriasis. M15-997

Mary M. Spolyar, MD

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Efficacy of KD025 in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis who are Candidates for Systemic Therapy or Phototherapy. KD025-211

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days – DFD06-CD-005

A Multicenter Open Label Uncontrolled Study of the long term safety and efficacy of calcitriol 3 mcg/g ointment applied twice daily for 26 weeks in pediatric subjects (2 to 16 years and 11 months of age) with mild to moderate plaque psoriasis. – RD.06.SPR.18131

Pharmacokinetics and pharmacodynamics of calcitriol 3mcg/g ointment applied twice daily for 14 days under conditions of maximal use in pediatric subjects (2 to 12 years of age) with plaque psoriasis – RD.06.SPR.18104

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis including those Previously Treated with Biologic Anti-TNF α Agent(s): CNTO1959PSA3001

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis. I4V-MC-JAIW

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of PF-04965842 Monotherapy in Subjects Aged 12 Years and Older, with Moderate to Severe Atopic Dermatitis. B7451012

Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RVT-501 Topical Ointment in Pediatric Patients with Atopic Dermatitis. RVT-501-2007

A Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy And Safety Of Dupilumab Monotherapy In Patients ≥ 12 To < 18 Years Of Age, With Moderate-To-Severe Atopic Dermatitis: R668-AD-1526

A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis - 203121

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients with Atopic Dermatitis - R668-AD-1415

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis - AN2728-AD-302

A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects with Rosacea - CLS001-CO-PR-006

A Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks DFD-03-CD-006

A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris FX2017-22

Mary M. Spolyar, MD

A Phase IV Open-Label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA® (isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne - ABS1517LT

A Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Phase IIb Dose-Finding Study of QGE031 as add-on therapy to investigate the efficacy and safety in patients with Chronic Spontaneous Urticaria (CSU) – CQGE031C2201

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to evaluate the clinical efficacy, safety, tolerability, dose relation, pharmacokinetics and pharmacodynamics of CJM112 in moderate to severe chronic hidradenitis suppurativa patients – CCJM112X2202

A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients with Chronic Idiopathic Urticaria – ML29510

A Phase III, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects with Actinic Keratosis on the Face or Scalp KX01-AK003

Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm² on the Chest – LP0105-1032

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream, 2.5% and Zyclara™ (imiquimod) Cream 2.5% in Subjects with Actinic Keratoses – 094-3153-301

License/Certifications/Training

Board Certified in Dermatology
Indiana State License #01047967A
CITI certification
ACLS Certified

Professional Societies

American Academy of Dermatology
American Academy of Dermatologic Surgery
Dermatology Foundation
Society of Military Dermatologists